The Centers for Medicare and Medicaid Services this week CMS adopted a new change that moves medication risk mitigation from the admin side to the patient care side of their medical loss ratio, Piper Jaffray analyst Sean Wieland tells investors in a research note. The analyst believes the revision represents a "significant opportunity" for Tabula Rasa's Enhanced Medication Therapy Management service as it could help mitigate price sensitivity on the EMTM upcharge, and accelerate growth. Wieland reiterates an Overweight rating on Tabula Rasa with a $43 price target.